FULC
Fulcrum TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Composite grade C from latest DB weights. Momentum 38.0 / Value 57.6
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-29.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
38
Value
58
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -Analysis date unavailable; returns require an exact persisted reference.
Earnings
2026-10-29
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $4.00
Why
Momentum38 · Δ7d -13.0
Value58 · Δ7d -0.1
SentimentN/A · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-29.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Mixed signals. Wait for cleaner trend confirmation.
Catalyst clock
2026-10-29
Lead driver: Value · See fundamentals
Momentum
38
15% active weight
Current posture
7d trendImproving
Δ7d
-13.0
Δ21d
+25.9
Value
58
85% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 38.0 / Value 57.6
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$280.77M
Beta
3.19
Shares Out
76.3M
P/E (TTM) · Derived
-3.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.90
Rev YoY
-100.0%
EPS YoY
+24.2%
Gross Margin
+98.1%
Op Margin
-15.6%
Net Debt
-$345.86M
Current Ratio
31.35
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data